REGENERON PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax
REGENERON PHARMACEUTICALS, INC. (REGN) reported Other Comprehensive Income (Loss), Net of Tax of $7.30 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2024-08-01
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-06-30 was $7.30M.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was $3.70M, a 93.53% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was $20.90M.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-06-30 was -$16.10M.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $157.90M.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$212.60M.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2021 was -$55.50M, a 776.83% decline from fiscal 2020.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2020 was $8.20M, a 75.45% decline from fiscal 2019.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | $7.30M 10-Q · filed 2024-08-01 | $11.00M derived: sum of 2 quarters · filed 2024-08-01 | |||
| 2024-03-31 | $3.70M 10-Q · filed 2024-08-01 | ||||
| 2023-12-31 | $157.90M 10-K · filed 2024-02-05 | ||||
| 2023-09-30 | $20.90M 10-Q · filed 2023-11-02 | $4.80M derived: sum of 2 quarters · filed 2024-08-01 | $62.00M derived: sum of 3 quarters · filed 2024-08-01 | ||
| 2023-06-30 | -$16.10M 10-Q · filed 2024-08-01 | $41.10M derived: sum of 2 quarters · filed 2024-08-01 | |||
| 2023-03-31 | $57.20M 10-Q · filed 2024-08-01 | ||||
| 2022-12-31 | -$212.60M 10-K · filed 2024-02-05 | ||||
| 2022-09-30 | -$51.30M 10-Q · filed 2023-11-02 | -$105.00M derived: sum of 2 quarters · filed 2023-11-02 | -$248.90M derived: sum of 3 quarters · filed 2023-11-02 | ||
| 2022-06-30 | -$53.70M 10-Q · filed 2023-11-02 | -$197.60M derived: sum of 2 quarters · filed 2023-11-02 | |||
| 2022-03-31 | -$143.90M 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | -$55.50M 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | -$6.20M 10-Q · filed 2022-11-03 | -$6.70M derived: sum of 2 quarters · filed 2022-11-03 | -$19.80M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | -$500.00K 10-Q · filed 2022-11-03 | -$13.60M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | -$13.10M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $8.20M 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | -$4.70M 10-Q · filed 2021-11-04 | $39.90M derived: sum of 2 quarters · filed 2021-11-04 | $9.70M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $44.60M 10-Q · filed 2021-11-04 | $14.40M derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | -$30.20M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | $33.40M 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $700.00K 10-Q · filed 2020-11-05 | $13.70M derived: sum of 2 quarters · filed 2020-11-05 | $28.80M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $13.00M 10-Q · filed 2020-11-05 | $28.10M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $15.10M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | -$6.30M 10-K · filed 2019-02-07 | ||||
| 2018-09-30 | $1.10M 10-Q · filed 2019-11-05 | $5.20M derived: sum of 2 quarters · filed 2019-11-05 | -$4.50M derived: sum of 3 quarters · filed 2019-11-05 | ||
| 2018-06-30 | $4.10M 10-Q · filed 2019-11-05 | -$5.60M derived: sum of 2 quarters · filed 2019-11-05 | |||
| 2018-03-31 | -$9.70M 10-Q · filed 2019-11-05 | ||||
| 2017-12-31 | $13.40M 10-K · filed 2019-02-07 | $13.48M 10-K · filed 2018-02-08 | |||
| 2016-12-31 | -$21.40M 10-K · filed 2019-02-07 | -$21.41M 10-K · filed 2018-02-08 | |||
| 2015-12-31 | -$43.68M 10-K · filed 2018-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |